Humana Provides Update on GLP-1 Prescriptions
PAAS National® has recently become aware of an update Humana published regarding new point-of-sale edits for specific medications. Included in this list are GLP-1 agonists.
Effective June 2023, Humana commercial, Medicare and Medicaid plans will now require diagnosis codes at point of sale in hopes of eliminating the “clinical misuse” of certain medications. Pharmacies can find this information posted on the Humana website under the Pharmacy Resources tab.
Be aware that a diagnosis field is likely not reviewed by the PBM unless the plan requires it on claim submission. Entering in a diagnosis code and receiving a paid claim does not affirm plan benefit design nor guarantee coverage.
Latest posts by Dana Westberg, CPhT (see all)
- The Need for Clarification on Prescription Labels - August 16, 2024
- 2024 Self-Audit Series #6: Return to Stock - August 6, 2024
- Ensuring Audit Readiness: What PBMs Look for in Signature Logs and Proof of Delivery - July 16, 2024